Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial - 01/10/11
, David Malka, MD a, Jean Mendiboure, MSc a, Pierre-Luc Etienne, MD c, Patrick Texereau, MD d, Dominique Auby, MD e, Philippe Rougier, ProfMD f, Mohamed Gasmi, MD g, Marine Castaing, MSc a, Moncef Abbas, MD a, Pierre Michel, ProfMD h, Dany Gargot, MD i, Ahmed Azzedine, MD j, Catherine Lombard-Bohas, MD k, Patrick Geoffroy, MD l, Bernard Denis, MD m, Jean-Pierre Pignon, MD a, Laurent Bedenne, ProfMD n, †, Olivier Bouché, ProfMD o, †for the Fédération Francophone de Cancérologie Digestive (FFCD) 2000–05 Collaborative Group‡
Summary |
Background |
The optimum use of cytotoxic drugs for advanced colorectal cancer has not been defined. Our aim was to investigate whether combination treatment is better than the sequential administration of the same drugs in patients with advanced colorectal cancer.
Methods |
In this open-label, randomised, phase 3 trial, we randomly assigned patients (1:1 ratio) with advanced, measurable, non-resectable colorectal cancer and WHO performance status 0–2 to receive either first-line treatment with bolus (400 mg/m2) and infusional (2400 mg/m2) fluorouracil plus leucovorin (400 mg/m2) (simplified LV5FU2 regimen), second-line LV5FU2 plus oxaliplatin (100 mg/m2) (FOLFOX6), and third-line LV5FU2 plus irinotecan (180 mg/m2) (FOLFIRI) or first-line FOLFOX6 and second-line FOLFIRI. Chemotherapy was administered every 2 weeks. Randomisation was done centrally using minimisation (minimisation factors were WHO performance status, previous adjuvant chemotherapy, number of disease sites, and centre). The primary endpoint was progression-free survival after two lines of treatment. Analyses were by intention-to-treat. This trial is registered at ClinicalTrials.gov, NCT00126256.
Findings |
205 patients were randomly assigned to the sequential group and 205 to the combination group. 161 (79%) patients in the sequential group and 161 (79%) in the combination group died during the study. Median progression-free survival after two lines was 10·5 months (95% CI 9·6–11·5) in the sequential group and 10·3 months (9·0–11·9) in the combination group (hazard ratio 0·95, 95% CI 0·77–1·16; p=0·61). All six deaths caused by toxic effects of treatment occurred in the combination group. During first-line chemotherapy, significantly fewer severe (grade 3–4) haematological adverse events (12 events in 203 patients in sequential group vs 83 events in 203 patients in combination group; p<0·0001) and non-haematological adverse events (26 events vs 186 events; p<0·0001) occurred in the sequential group than in the combination group.
Interpretation |
Upfront combination chemotherapy is more toxic and is not more effective than the sequential use of the same cytotoxic drugs in patients with advanced, non-resectable colorectal cancer.
Funding |
Sanofi-Aventis France.
Le texte complet de cet article est disponible en PDF.Plan
Vol 12 - N° 11
P. 1032-1044 - octobre 2011 Retour au numéro
Article précédent
- Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies
- Xavier Castellsagué, Mireia Díaz, Salvatore Vaccarella, Silvia de Sanjosé, Nubia Muñoz, Rolando Herrero, Silvia Franceschi, Chris J L M Meijer, F Xavier Bosch
- Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
- Patrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, Nguyen Bin Bui, Sebastian Bauer, Joerg Thomas Hartmann, Anders Krarup-Hansen, Viktor Grünwald, Raf Sciot, Herlinde Dumez, Jean-Yves Blay, Axel Le Cesne, Jantien Wanders, Carolyn Hayward, Sandrine Marreaud, Monia Ouali, Peter Hohenberger, for the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG)
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?